Patients with newly diagnosed exudative AMD continued their treatment regiments and received anti-VEGF therapy in 98%, 96%, and 85% of patients in the monthly, EOM, and sham groups respectively. This evidence concerns the gene VEGFA and age-related macular degeneration.